JP2007523089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523089A5 JP2007523089A5 JP2006553342A JP2006553342A JP2007523089A5 JP 2007523089 A5 JP2007523089 A5 JP 2007523089A5 JP 2006553342 A JP2006553342 A JP 2006553342A JP 2006553342 A JP2006553342 A JP 2006553342A JP 2007523089 A5 JP2007523089 A5 JP 2007523089A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nucleic acid
- binding
- antagonist
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54573004P | 2004-02-17 | 2004-02-17 | |
| US60/545,730 | 2004-02-17 | ||
| PCT/US2005/004743 WO2005079844A2 (en) | 2004-02-17 | 2005-02-15 | Use for interleukin-33 (il33) and the il-33 receptor complex |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131646A Division JP2011178810A (ja) | 2004-02-17 | 2011-06-13 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523089A JP2007523089A (ja) | 2007-08-16 |
| JP2007523089A5 true JP2007523089A5 (https=) | 2008-03-21 |
| JP4949859B2 JP4949859B2 (ja) | 2012-06-13 |
Family
ID=34886190
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553342A Expired - Lifetime JP4949859B2 (ja) | 2004-02-17 | 2005-02-15 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
| JP2011131646A Pending JP2011178810A (ja) | 2004-02-17 | 2011-06-13 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
| JP2014030239A Pending JP2014098026A (ja) | 2004-02-17 | 2014-02-20 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
| JP2015163939A Pending JP2016034948A (ja) | 2004-02-17 | 2015-08-21 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131646A Pending JP2011178810A (ja) | 2004-02-17 | 2011-06-13 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
| JP2014030239A Pending JP2014098026A (ja) | 2004-02-17 | 2014-02-20 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
| JP2015163939A Pending JP2016034948A (ja) | 2004-02-17 | 2015-08-21 | インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20050203046A1 (https=) |
| EP (2) | EP2283860A3 (https=) |
| JP (4) | JP4949859B2 (https=) |
| CN (1) | CN1917902A (https=) |
| AT (1) | ATE496636T1 (https=) |
| AU (1) | AU2005215528B2 (https=) |
| BR (1) | BRPI0507808A (https=) |
| CA (1) | CA2555236C (https=) |
| DE (1) | DE602005026105D1 (https=) |
| NO (1) | NO20064193L (https=) |
| NZ (1) | NZ549040A (https=) |
| TW (2) | TW201304802A (https=) |
| WO (1) | WO2005079844A2 (https=) |
| ZA (1) | ZA200606844B (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK3072978T3 (en) | 2002-05-09 | 2018-09-17 | Brigham & Womens Hospital Inc | : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2009511572A (ja) * | 2005-10-16 | 2009-03-19 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法 |
| DK2848938T3 (da) | 2006-04-24 | 2017-11-13 | Critical Care Diagnostics Inc | Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer |
| EP2021799B1 (en) * | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PT2021796E (pt) * | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
| ES2723957T3 (es) * | 2006-05-02 | 2019-09-04 | Critical Care Diagnostics Inc | Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
| US8147817B2 (en) * | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| SE532250C2 (sv) * | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| WO2008144610A1 (en) * | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| JP5526122B2 (ja) | 2008-04-18 | 2014-06-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 主要有害心イベントのリスクを予測する方法 |
| JP5539660B2 (ja) * | 2009-03-10 | 2014-07-02 | 公益財団法人ヒューマンサイエンス振興財団 | 粘膜ワクチン用アジュバント |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| EP2678358B1 (en) | 2011-02-23 | 2015-07-22 | F.Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JP6450679B2 (ja) | 2012-08-21 | 2019-01-09 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | マルチマーカーリスク層別化 |
| WO2014090800A1 (en) * | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
| KR101780575B1 (ko) * | 2013-02-14 | 2017-09-21 | 건국대학교 산학협력단 | 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도 |
| EP2958583B1 (en) * | 2013-02-22 | 2018-04-11 | Magic Epoch Holdings Limited | Il-33 and treatment of neurodegenerative diseases |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EP2968454B1 (en) | 2013-03-15 | 2019-02-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| EP3782628B1 (en) | 2013-03-15 | 2024-08-07 | Elixirgen Therapeutics, Inc. | Methods of using zscan4 for rejuvenating human cells |
| US9840545B2 (en) | 2013-09-20 | 2017-12-12 | University Of Virginia Patent Foundation | Fusion protein comprising interleukin-2 and interleukin-33 |
| DK3054972T3 (da) * | 2013-10-07 | 2019-06-11 | Univ Pennsylvania | Vacciner med interleukin-33 som et adjuvans |
| EP3088517B1 (en) * | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| ES2866935T3 (es) * | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| EP3119913B1 (en) | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| WO2015164354A1 (en) | 2014-04-21 | 2015-10-29 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| CR20170240A (es) * | 2014-11-10 | 2018-04-03 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| EP3265493B1 (en) | 2015-03-02 | 2024-01-10 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| WO2016138590A1 (en) * | 2015-03-03 | 2016-09-09 | Wilfred Jefferies | Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44 |
| HRP20210096T1 (hr) | 2015-03-31 | 2021-03-05 | Medimmune Limited | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe |
| JP6501650B2 (ja) * | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | ヒト抗ｉｌ−３３中和モノクローナル抗体 |
| EP3331551B1 (en) * | 2015-07-10 | 2021-06-23 | The Hong Kong University of Science and Technology | Compositions for use in treating neurodegenerative and neuroinflammatory conditions |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| KR101765397B1 (ko) | 2015-12-02 | 2017-08-07 | 한국과학기술원 | 질점막을 통한 바이러스 감염 취약 진단 마커로서의 il-33의 용도 |
| MX2018013038A (es) | 2016-04-27 | 2019-03-28 | Pfizer | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. |
| WO2018005682A2 (en) | 2016-06-29 | 2018-01-04 | Checkpoint Therapeutics, Inc. | Pd-l1-specific antibodies and methods of using the same |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| JP6995127B2 (ja) | 2017-02-10 | 2022-02-04 | ジェネンテック， インコーポレイテッド | 抗トリプターゼ抗体、その組成物、及びその使用 |
| US20200339674A1 (en) * | 2017-02-17 | 2020-10-29 | The General Hospital Corporation | Methods and compositions for treating a brain injury |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| KR102872720B1 (ko) | 2017-05-05 | 2025-10-16 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 기질 결합 소낭의 안구에의 적용 |
| IL272864B2 (en) | 2017-08-31 | 2024-03-01 | Mitsubishi Tanabe Pharma Corp | Il-33 antagonist-containing therapeutic agent for endometriosis |
| KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| IL307286B2 (en) | 2018-04-11 | 2026-03-01 | Regeneron Pharma | Methods and reagents for IL-33 quantification |
| KR20210005942A (ko) * | 2018-05-03 | 2021-01-15 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Il-33을 포함하는 매트릭스 결합 소포 (mbvs) 및 그 용도 |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| TW202519263A (zh) | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| US12594324B2 (en) | 2019-06-30 | 2026-04-07 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treatment of pancreatic cancer |
| WO2021068196A1 (en) * | 2019-10-11 | 2021-04-15 | General Regeneratives (Shanghai) Limited | Methods of using il-33 protein in treating cancers |
| WO2021089563A1 (en) * | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| PE20230252A1 (es) | 2020-03-13 | 2023-02-07 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos de estos |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| CN112210556A (zh) * | 2020-10-15 | 2021-01-12 | 扬州大学 | 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用 |
| EP4430072A1 (en) | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN114426981B (zh) * | 2022-02-21 | 2022-11-29 | 吉林农业大学 | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| CN118185884A (zh) * | 2023-10-16 | 2024-06-14 | 王琪 | 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
| WO1992010210A1 (en) * | 1990-12-14 | 1992-06-25 | E.I. Du Pont De Nemours And Company | Inhibition of angiogenesis by il-1 |
| US5571702A (en) | 1991-03-29 | 1996-11-05 | Genentech, Inc. | Amplification method for detection of human PF4A receptors |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US5576191A (en) * | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
| DK1027437T3 (da) | 1997-10-29 | 2008-11-24 | Genentech Inc | Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1 |
| IL136696A0 (en) * | 1997-12-23 | 2001-06-14 | Immunex Corp | Sigirr dna and polypeptides |
| GB9727172D0 (en) * | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| KR100537558B1 (ko) | 1998-09-01 | 2005-12-19 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 인터류킨-18 결합 단백질 |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001046697A2 (en) | 1999-12-21 | 2001-06-28 | Millennium Predictive Medicine | Identification, assessment, prevention, and therapy of breast cancer |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP1385993B8 (en) | 2000-12-08 | 2011-09-21 | Celldex Therapeutics, Inc. | Method of detecting and treating tuberous sclerosis complex associated disorders |
| US20040009481A1 (en) * | 2001-06-11 | 2004-01-15 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| AU2001289843A1 (en) | 2001-08-28 | 2002-02-13 | Bayer Cropscience Ag | Polypeptides for identifying herbicidally active compounds |
| US20070042978A1 (en) * | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| JP2007537717A (ja) | 2004-01-07 | 2007-12-27 | ブリストル−マイヤーズ スクイブ カンパニー | 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| WO2008144610A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
-
2004
- 2004-11-29 NZ NZ549040A patent/NZ549040A/xx not_active IP Right Cessation
-
2005
- 2005-02-15 BR BRPI0507808-3A patent/BRPI0507808A/pt not_active IP Right Cessation
- 2005-02-15 DE DE602005026105T patent/DE602005026105D1/de not_active Expired - Lifetime
- 2005-02-15 EP EP10177117.8A patent/EP2283860A3/en not_active Withdrawn
- 2005-02-15 WO PCT/US2005/004743 patent/WO2005079844A2/en not_active Ceased
- 2005-02-15 AT AT05713577T patent/ATE496636T1/de not_active IP Right Cessation
- 2005-02-15 US US11/059,117 patent/US20050203046A1/en not_active Abandoned
- 2005-02-15 CN CNA2005800050705A patent/CN1917902A/zh active Pending
- 2005-02-15 AU AU2005215528A patent/AU2005215528B2/en not_active Ceased
- 2005-02-15 CA CA2555236A patent/CA2555236C/en not_active Expired - Lifetime
- 2005-02-15 EP EP05713577A patent/EP1725261B1/en not_active Expired - Lifetime
- 2005-02-15 JP JP2006553342A patent/JP4949859B2/ja not_active Expired - Lifetime
- 2005-02-16 TW TW101117025A patent/TW201304802A/zh unknown
- 2005-02-16 TW TW094104561A patent/TWI372628B/zh not_active IP Right Cessation
-
2006
- 2006-08-15 ZA ZA200606844A patent/ZA200606844B/xx unknown
- 2006-09-15 NO NO20064193A patent/NO20064193L/no not_active Application Discontinuation
-
2007
- 2007-03-05 US US11/682,224 patent/US20070160579A1/en not_active Abandoned
-
2008
- 2008-09-26 US US12/239,689 patent/US20090041718A1/en not_active Abandoned
-
2011
- 2011-06-13 JP JP2011131646A patent/JP2011178810A/ja active Pending
-
2014
- 2014-02-03 US US14/171,629 patent/US9970944B2/en active Active
- 2014-02-20 JP JP2014030239A patent/JP2014098026A/ja active Pending
-
2015
- 2015-08-21 JP JP2015163939A patent/JP2016034948A/ja active Pending
-
2017
- 2017-12-20 US US15/848,417 patent/US20180128837A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523089A5 (https=) | ||
| US20260049993A1 (en) | Viral serology assays | |
| US20210405059A1 (en) | Biomarkers for early determination of a critical or life threatening response to illness and/or treatment response | |
| CN108802385B (zh) | 用于诊断感染的标记和决定因素和其使用方法 | |
| EP3475702B3 (en) | Measuring trail by lateral flow immunoassay | |
| US20210389308A1 (en) | Detecting adaptive immunity to coronavirus | |
| US10822406B2 (en) | Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR) | |
| EP3482201B1 (en) | Early diagnosis of infections | |
| US10247730B2 (en) | Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient | |
| EP4141448A1 (en) | Protein signatures for distinguishing between bacterial and viral infections | |
| US8367350B2 (en) | Compositions and methods for diagnosis, prognosis and management of malaria | |
| WO2010025393A2 (en) | Protein biomarkers and methods for diagnosing kawasaki disease | |
| JP2012509477A5 (https=) | ||
| JP2007523088A5 (https=) | ||
| WO2016059636A1 (en) | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof | |
| WO2016028699A2 (en) | Biomarkers for diagnosis and management of neuro-immunological diseases | |
| CN111133313A (zh) | 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途 | |
| RU2697549C2 (ru) | Биомаркеры для туберкулеза | |
| JP2010536043A5 (https=) | ||
| EP3289358A1 (en) | Novel design of enzyme-linked immunsorbent assay plates and systems and methods of use thereof | |
| JP2014518624A5 (https=) | ||
| JP2021523375A (ja) | 疾病の予後と管理のための方法 | |
| EP4591062A1 (en) | Orthopoxvirus serology assays | |
| WO2013114064A1 (en) | Methods and devices for diagnosis of serious bacterial infection | |
| WO2023034933A1 (en) | Methods and systems for assessing adaptive immunity to coronavirus |